5.165
Verastem Inc stock is traded at $5.165, with a volume of 796.04K.
It is up +1.08% in the last 24 hours and up +4.56% over the past month.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
See More
Previous Close:
$5.10
Open:
$5.1
24h Volume:
796.04K
Relative Volume:
0.37
Market Cap:
$283.54M
Revenue:
$3.64M
Net Income/Loss:
$-87.37M
P/E Ratio:
-1.2567
EPS:
-4.11
Net Cash Flow:
$-86.46M
1W Performance:
+5.42%
1M Performance:
+4.56%
6M Performance:
-6.61%
1Y Performance:
+50.73%
Verastem Inc Stock (VSTM) Company Profile
Name
Verastem Inc
Sector
Industry
Phone
(781) 292-4200
Address
117 KENDRICK STREET, NEEDHAM, MA
Compare VSTM with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
VSTM
Verastem Inc
|
5.16 | 272.55M | 3.64M | -87.37M | -86.46M | -4.11 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
468.96 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
556.83 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.82 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
574.62 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
294.65 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Verastem Inc Stock (VSTM) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-10-25 | Initiated | Jefferies | Buy |
Mar-24-25 | Reiterated | H.C. Wainwright | Buy |
Dec-31-24 | Reiterated | BTIG Research | Buy |
Sep-30-24 | Initiated | Guggenheim | Buy |
Nov-21-23 | Resumed | BTIG Research | Buy |
Sep-27-23 | Initiated | B. Riley Securities | Buy |
Jun-15-23 | Upgrade | Mizuho | Neutral → Buy |
Sep-07-22 | Resumed | Alliance Global Partners | Buy |
Apr-29-22 | Resumed | Cantor Fitzgerald | Overweight |
Apr-14-22 | Initiated | RBC Capital Mkts | Outperform |
Mar-09-22 | Initiated | Truist | Buy |
Jul-01-21 | Initiated | Alliance Global Partners | Buy |
May-24-21 | Upgrade | BTIG Research | Neutral → Buy |
Jun-20-19 | Downgrade | BTIG Research | Buy → Neutral |
May-10-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
Jul-13-18 | Initiated | BTIG Research | Buy |
May-02-18 | Initiated | Seaport Global Securities | Buy |
Mar-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
Sep-07-17 | Reiterated | H.C. Wainwright | Buy |
Apr-13-17 | Initiated | Oppenheimer | Outperform |
Mar-24-17 | Reiterated | H.C. Wainwright | Buy |
Sep-29-15 | Downgrade | Cantor Fitzgerald | Buy → Hold |
Sep-29-15 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
Sep-29-15 | Downgrade | Jefferies | Buy → Hold |
Sep-29-15 | Downgrade | Raymond James | Strong Buy → Outperform |
Sep-28-15 | Downgrade | Mizuho | Buy → Neutral |
Sep-28-15 | Downgrade | ROTH Capital | Buy → Neutral |
Sep-09-15 | Initiated | Raymond James | Strong Buy |
May-12-15 | Reiterated | UBS | Buy |
Apr-08-15 | Initiated | H.C. Wainwright | Buy |
Jan-23-15 | Reiterated | ROTH Capital | Buy |
Jul-08-14 | Resumed | Oppenheimer | Perform |
Feb-11-14 | Initiated | Mizuho | Buy |
View All
Verastem Inc Stock (VSTM) Latest News
(VSTM) Proactive Strategies - news.stocktradersdaily.com
What analysts say about Verastem Inc. stockFree Daily Trading Room Entry - Autocar Professional
Is Verastem Inc. a good long term investmentConsistent triple-digit returns - jammulinksnews.com
What drives Verastem Inc. stock priceBreakthrough stock performance - Autocar Professional
Verastem Inc. Stock Analysis and ForecastFree Market Dynamics Reports - jammulinksnews.com
Verastem’s Promising KRAS G12D Inhibitor Study: A Potential Game-Changer in Cancer Treatment - TipRanks
Verastem: The Market Is Ignoring The Progress (NASDAQ:VSTM) - Seeking Alpha
Why Verastem Inc. stock attracts strong analyst attentionDaily Trade Opportunity - beatles.ru
What makes Verastem Inc. stock price move sharplyEntry Level Low Risk Picks - Newser
How Verastem Inc. stock performs during market volatilityFast Moving Stock Alerts - Newser
Avutometinib-Defactinib: A New Standard in Precision Oncology? - AInvest
Verastem’s avutometinib combination shows 31% ORR in ovarian cancer trial - Yahoo Finance
Verastem Oncology's Breakthrough in LGSOC: A New Standard of Care with Substantial Upside Potential - AInvest
Verastem’s cancer drug shows 31% response rate in ovarian cancer trial By Investing.com - Investing.com Canada
Verastem stock rises after LGSOC treatment data published in medical journal - Investing.com
Verastem stock rises after LGSOC treatment data published in medical journal By Investing.com - Investing.com South Africa
Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology - Yahoo Finance
KRAS Inhibitors Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Target Population, Revenue, Statistics, MOA, ROA and Companies DelveInsight - Barchart.com
Verastem Oncology's Talent Incentives: Balancing Equity Dilution and Growth - AInvest
Verastem Oncology announces inducement grants under Nasdaq listing rule - MarketScreener
Verastem Oncology Awards 45,000 Share Options at $4.29 Each to Expand Cancer Drug Development Team - Stock Titan
Verastem’s Phase 3 Study on Avutometinib and Defactinib: A Potential Game-Changer for Ovarian Cancer Treatment - TipRanks
Verastem’s Promising Phase 3 Study on Recurrent Ovarian Cancer - TipRanks
How the (VSTM) price action is used to our Advantage - news.stocktradersdaily.com
Verastem’s Promising Phase 3 Study on Avutometinib and Defactinib in Ovarian Cancer - TipRanks
Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Verastem: Approval Secured, Moving On To PDAC And KRAS G12D-Related Cancers - Seeking Alpha
Verastem (VSTM) Target Price Lowered by RBC Capital | VSTM Stock News - GuruFocus
RBC Capital Adjusts Target Price for Verastem (VSTM) to $12 | VSTM Stock News - GuruFocus
Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors - BioSpace
Verastem Executives Sell Shares to Meet Tax Obligations - TradingView
Verastem CEO Paterson sells $1.8k in shares By Investing.com - Investing.com Canada
Verastem’s SWOT analysis: biotech stock poised for growth amid challenges By Investing.com - Investing.com South Africa
Verastem’s SWOT analysis: biotech stock poised for growth amid challenges - Investing.com
(VSTM) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Verastem Announces Positive Data From Cancer Trial Conducted By Partner: Retail Turns Bullish - MSN
ASCO 2025: Verastem has positive cancer data but stock sags - BioWorld MedTech
Cantor Fitzgerald reiterates overweight rating on Verastem stock By Investing.com - Investing.com Nigeria
Transcript : Verastem, Inc.Special Call - marketscreener.com
What's Going On With Verastem Oncology Stock On Monday? - Benzinga
Verastem Inc Stock (VSTM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):